F-box protein 22: A prognostic biomarker for colon cancer associated with immune infiltration and chemotherapy resistance  

作　　者：Xiao-Fei Lu Hong-Wei Zhang Xiao Chang Yong-Ze Guo 

机构地区：[1]Department of Clinical Medicine,Hebei University of Engineering,Handan 056002,Hebei Province,China [2]Department of Gastroenterology,Affiliated Hospital of Hebei Engineering University,Handan 056002,Hebei Province,China

出　　处：《World Journal of Gastrointestinal Oncology》2025年第4期365-383,共19页世界胃肠肿瘤学杂志(英文)

基　　金：The study was reviewed and approved by institutional ethics board of Affiliated Hospital of Hebei Engineering University(No.:2024[K]005-01).

摘　　要：BACKGROUND Colon cancer represents a significant malignant neoplasm within the digestive system,characterized by a high incidence rate and substantial disease burden.The F-box protein 22(FBXO22)plays a role in forming a specific type of ubiquitin ligase subunit,which is expressed abnormally in various malignant neoplasms and shows a notable relationship with prognosis in patients with cancer.Never-theless,the function of FBXO22 in the context of colon cancer remains inade-quately elucidated.AIM To explore the role of FBXO22 in colon cancer by examining FBXO22 expression patterns and analyzing how the protein affects the prognosis in patients who have undergone surgery.METHODS Samples of cancerous and nearby normal tissues from patients with colon cancer were gathered,along with pertinent clinical data.Expression levels of the FBXO22 gene in both cancerous and paracancerous tissues were assessed through immu-nohistochemistry.The median H score served as a criterion for categorizing FBXO22 gene expression into high and low levels in cancerous tissues,and the relationship between these expression levels and various pathologic character-istics of patients,such as age,sex,and clinical stage,was analyzed.Colon cancer cell lines HCT116 and DLD-1 were used and divided into three groups:A blank control group,a negative control group,and a si-FBXO22 group.FBXO22 gene mRNA and protein expression were measured 24 hours post-transfection using real-time fluorescence quantitative polymerase chain reaction and western blotting.The proliferation capabilities of the cells in each group were assessed using the Cell Counting Kit-8 assay and 5-ethynyl-2’-deoxyuridine assay,while cellular migration and invasion abilities were evaluated using scratch healing and Transwell assays.Various online platforms,including the Timer Immune Estimation Resource,were used to analyze pan-cancer expression,promoter methylation levels,and mutation frequencies of the FBXO22 gene in colon cancer patients.Additionally,the correlation between FBXO22 ge

关 键 词：Colorectal cancer F-box protein 22 BIOMARKER PROGNOSIS Tumor immunology 

分 类 号：R73[医药卫生—肿瘤]